Blog
RSS FeedPosted by Michael Wonder on 11 Nov 2021
Bolstering our ability to value health technology: a few less considered issues
9 November 2021 - Proposals for a national entity to produce and assess evidence about the relative value of medical technology ...
Posted by Michael Wonder on 04 Jul 2021
ICER to test principle of fair access to fairly priced pharmaceuticals
2 July 2021 - The controversial approval last month by the FDA of Aduhelm (aducanumab) for patients with early-stage Alzheimer’s disease ...
Posted by Michael Wonder on 25 May 2021
ICER publishes protocol for first annual assessment of drug coverage policies that present barriers to fair access
25 May 2021 - ICER’s analysis, based on MMIT’s market access analytics solution, will evaluate how 15 of the largest ...
Posted by Michael Wonder on 26 Apr 2021
ICER publishes white paper evaluating policy options to strengthen FDA’s accelerated approval pathway for prescription drugs
26 April 2021 - Informed by expert input from patient groups, former regulators, payers, and life science companies, white paper analyses ...
Posted by Michael Wonder on 02 Jul 2020
ICER publishes white paper on alternative policies for drug and vaccine pricing during a pandemic, announces cross-stakeholder discussion series
2 July 2020 - The Institute for Clinical and Economic Review today published a white paper to inform public and policy ...
Posted by Michael Wonder on 18 Mar 2018
Policy strategies for aligning price and value for brand-name pharmaceuticals
15 March 2018 - Systemic factors in the US health care system lead to greater pricing power for drug manufacturers than ...